Friday, October 20th | 30 Tishri 5778

Close

Be in the know!

Get our exclusive daily news briefing.

Subscribe
May 29, 2017 11:02 am

Israeli Researchers Develop New ALS Treatment

avatar by JNS.org

Email a copy of "Israeli Researchers Develop New ALS Treatment" to a friend

An MRI that is consistent with a diagnosis of ALS. Photo: Frank Gaillard via Wikimedia Commons.

JNS.org – Researchers at Israel’s Ben-Gurion University of the Negev (BGU) announced the development of a new treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

The lethal neurodegenerative disorder causes deterioration in the brain and spinal cord’s motor nerve cells, leading to atrophy, paralysis and eventually death caused by a complete breakdown of the respiratory muscles.

BGU researcher Dr. Rachel Lichtenstein has developed a new method for slowing the advancement of ALS by successfully redesigning a segment of FDA-approved drug MabThera — used to treat autoimmune diseases and certain types of cancer — into a new molecule for treating ALS.

“Our experimental results on ALS transgenic mice showed a significant increase in life expectancy,” said Lichtenstein. “Since the drug is already approved, we believe that we will only need limited preclinical testing to reach the clinical phase earlier than other initiatives.”

Related coverage

October 19, 2017 7:40 pm
2

Senior UK Jewish Leader Criticizes British UN Diplomat Over Balfour Declaration Comments to UN Security Council

The top organization representing British Jews has lodged a complaint with the British government over remarks by the UK's Deputy Ambassador to...

Dr. Ora Horovitz, senior vice president of business development at BGN Technologies, BGU’s technology transfer and commercialization company said, “This could also have major implications on the life expectancy of other neurodegenerative disease patients with Alzheimer’s and Parkinson’s.” The new drug candidate, she said, could improve “the lives of millions of people.”

BGU researchers are seeking a pharmaceutical company to partner with the university on the initiative.

Share this Story: Share On Facebook Share On Twitter Email This Article

Let your voice be heard!

Join the Algemeiner
  • Hard Little Machine

    It is imperative we get all the Israel haters to sign on to a personal and institutional boycott of this.

Algemeiner.com